Building IP: SGMO Patent Grant "Engineered Target Specific Base Editors" | SGMO Message Board Posts


Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  177092 of 178609  at  12/5/2023 2:33:20 PM  by

nocashonhand


 In response to msg 177091 by  dachmeister4u
view thread

Re: Building IP: SGMO Patent Grant "Engineered Target Specific Base Editors"

Marty, please weigh in on dachmeister's wondering. Or possibly just provide any significance at all of Sangamo's so called notable "Patent Estate". Personally I don't have an ounce of belief there is any significance with the paragraph below. And as it regards to ZF tech, I think the market and big pharma are speaking loud and clear. 
 
"

Patent Estate

Sangamo has prioritized intellectual property as an essential component of their business. They have a dominant proprietary patent estate for zinc fingers design and methods. They also own more CRISPR patents than CRISRP (CRSP), Editas (EDIT) and Intellia (NTLA) combined. The 2019 CRISPR 10k states they own approximately 25 granted patents worldwide, relying primarily on in-licensing which is clouded by ongoing patent litigation."

 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...